Department of Chemistry and Exact Sciences, Southwestern Bahia State University, Jequié, Brazil.
J Bras Pneumol. 2013 Jun-Aug;39(4):409-17. doi: 10.1590/S1806-37132013000400003.
To describe and characterize local adverse effects (in the oral cavity, pharynx, and larynx) associated with the use of inhaled corticosteroids (ICSs) in patients with moderate or severe asthma.
This was a cross-sectional study involving a convenience sample of 200 asthma patients followed in the Department of Pharmaceutical Care of the Bahia State Asthma and Allergic Rhinitis Control Program Referral Center, located in the city of Salvador, Brazil. The patients were ≥ 18 years of age and had been using ICSs regularly for at least 6 months. Local adverse effects (irritation, pain, dry throat, throat clearing, hoarseness, reduced vocal intensity, loss of voice, sensation of thirst, cough during ICS use, altered sense of taste, and presence of oral candidiasis) were assessed using a 30-day recall questionnaire.
Of the 200 patients studied, 159 (79.5%) were women. The mean age was 50.7 ± 14.4 years. In this sample, 55 patients (27.5%) were using high doses of ICS, with a median treatment duration of 38 months. Regarding the symptoms, 163 patients (81.5%) reported at least one adverse effect, and 131 (65.5%) had a daily perception of at least one symptom. Vocal and pharyngeal symptoms were identified in 57 (28.5%) and 154 (77.0%) of the patients, respectively. The most commonly reported adverse effects were dry throat, throat clearing, sensation of thirst, and hoarseness.
Self-reported adverse effects related to ICS use were common among the asthma patients evaluated here.
描述和分析与中重度哮喘患者使用吸入性皮质类固醇(ICS)相关的局部不良反应(口腔、咽部和喉部)。
这是一项横断面研究,纳入了巴西萨尔瓦多市巴伊亚州哮喘和过敏性鼻炎控制计划转诊中心药学服务部门的 200 名哮喘患者,这些患者年龄均≥18 岁,且规律使用 ICS 至少 6 个月。使用 30 天回顾性调查问卷评估局部不良反应(刺激、疼痛、咽干、清嗓、声音嘶哑、发声减弱、声音丧失、口渴感、ICS 使用时咳嗽、味觉改变和口腔念珠菌病)。
在研究的 200 名患者中,159 名(79.5%)为女性,平均年龄为 50.7±14.4 岁。在该样本中,55 名(27.5%)患者使用高剂量 ICS,中位治疗持续时间为 38 个月。关于症状,163 名(81.5%)患者报告至少有一种不良反应,131 名(65.5%)每天至少有一种症状。57 名(28.5%)和 154 名(77.0%)患者分别出现了声音和咽部症状。最常报告的不良反应是咽干、清嗓、口渴和声音嘶哑。
在这里评估的哮喘患者中,自我报告的与 ICS 使用相关的不良反应很常见。